AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

AdAlta announces two significant additions to its AdCella (East to West cell therapies for solid cancers) and AdSolis (AD-214: a new approach to fibrosis) leadership teams

Kevin Lynch MD, Consultant Chief Medical Officer (CMO)-AdCella, brings 25 years’ experience in clinical development of haematology/oncology drugs, including in China, at Antengene, Celgene and Novartis

A Consultant CMO-AdSolis is also being appointed. They will bring extensive experience in respiratory and orphan drug development, including clinical development leadership roles in drugs for IPF

Both appointments will help support the anticipated near-term increase in clinical trial preparation and execution activity associated with AdCella’s intended solid cancer cellular immunotherapy pipeline and AdSolis’ intended further clinical trials of AD-214

Chief Medical Officer Appointments

Summary